Continuous Glucose Monitoring in the Intensive Care Unit.
Lizda Guerrero-ArroyoEileen R FauldsM Citlalli Perez-GuzmanGeorgia M DavisKathleen M DunganFrancisco J PasquelPublished in: Journal of diabetes science and technology (2023)
Traditionally, the care of critically ill patients with diabetes or stress hyperglycemia in the intensive care unit (ICU) demands the use of continuous intravenous insulin (CII) therapy to achieve narrow glycemic targets. To reduce the risk of iatrogenic hypoglycemia and to achieve glycemic targets during CII, healthcare providers (HCP) rely on hourly point-of-care (POC) arterial or capillary glucose tests obtained with glucose monitors. The burden of this approach, however, was evident during the beginning of the pandemic when the immediate reduction in close contact interactions between HCP and patients with COVID-19 was necessary to avoid potentially life-threatening exposures. Taking advantage of the advancements in current diabetes technologies, including continuous glucose monitoring (CGM) devices integrated with digital health tools for remote monitoring, HCP implemented novel protocols in the ICU to care for patients with COVID-19 and hyperglycemia. We provide an overview of research conducted in the ICU setting with the use of initial CGM technology to current devices and summarize our recent experience in the ICU.
Keyphrases
- healthcare
- type diabetes
- glycemic control
- intensive care unit
- mechanical ventilation
- blood glucose
- palliative care
- sars cov
- affordable care act
- cardiovascular disease
- mental health
- quality improvement
- public health
- risk factors
- air pollution
- diabetic rats
- acute respiratory distress syndrome
- stem cells
- weight loss
- climate change
- blood pressure
- oxidative stress
- metabolic syndrome
- high dose
- pain management
- bone marrow
- human health